Hologic today announced that the jury in the patent infringement lawsuit against SenoRx brought by Hologic, Cytyc Corp., and Hologic L.P., Inc. in the U.S. District Court for the Northern District of California has returned a verdict in favor of SenoRx.

Hologic today announced that Rob Cascella, President and Chief Executive Officer, and Glenn Muir, Chief Financial Officer, will present at the 28th Annual J.P. Morgan Healthcare Conference, January 12, 2010, at 3:30 p.m. (Pacific).

Hologic today announced the Company will host a meeting for members of the investment community at the RSNA (Radiological Society of North America) trade show in Chicago, IL.

Hologic, Inc. (NASDAQ: HOLX) today announced that Jack Cumming, Chairman, will present at the NASDAQ OMX 23rd Investor Program in London on Tuesday, December 1, 2009, at 11:15am. (GMT).

Hologic is using the annual meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago, November 29 through December 3, 2009 to highlight our new SecurView® DX multimodality diagnostic mammography workstation software.

On November 16th, the U.S. Preventive Services Task Force (USPSTF), an independent panel of doctors and scientists that make recommendations to the U.S. Department of Health and Human Services, announced a change to their mammography screening guidelines.

Hologic is participating in the 38th Annual American Association of Gynecologic Laparoscopists (AAGL) conference, November 15-19, 2009 in Orlando, Florida, and will feature its Adiana® permanent contraception system.

Hologic is using the annual meeting of the American Society for Radiology Oncology (ASTRO) at McCormick Place in Chicago, November 1 through 5, 2009, to feature the MammoSite® ML radiation therapy system.

Hologic today announced that Glenn Muir, Chief Financial Officer, will present at Citi’s 2009 Sixth Annual Small/Mid Cap Conference in New York City on Thursday, November 19, 2009, at 9:10 a.m. (EST).

Hologic today announced the opening of its new Asia Pacific regional offices and the Hologic Asia Pacific Center for Health Sciences Education in Hong Kong. Sales, product support, training, R&D, logistics, health sciences education, and service for Hologic’s breast health, diagnostics, GYN surgical, and skeletal health businesses for the Asia Pacific market will be coordinated from the new facility.

Hologic today announced it has received CE marking approval for its ThinPrep® integrated imager. The ThinPrep integrated imager was introduced and on display at the 35th European Congress of Cytology this week in Lisbon, Portugal.

Hologic today announced that Jack Cumming, Hologic Chairman and CEO, will preside over the NASDAQ opening bell ceremony in New York City on Thursday, October 1, 2009 at 9:30 a.m. (EST) for the fourth consecutive year to honor the National Breast Cancer Awareness Month and to kick off Hologic’s “Promise to Me” campaign.

Hologic today announced the United Kingdom’s National Institute for Health and Clinical Excellence (NICE), in its updated guidance for hysteroscopic sterilization, supports the use of Hologic’s Adiana® permanent contraception system.

Hologic today announced that Glenn Muir, Chief Financial Officer, will present at the 2009 Morgan Stanley Global Healthcare Unplugged Conference in New York City on Tuesday, September 15, 2009, at 2:45 p.m. (Eastern).

Hologic today announced the U.S. Food and Drug Administration (FDA) cleared the Company’s 510K application for the MammoSite® ML radiation therapy system.

Hologic today announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth.

Hologic , today announced its NovaSure® system–a 90-second, outpatient treatment for women suffering from excessive menstrual bleeding–has passed the one million mark for number of procedures performed.

Hologic today announced that Glenn Muir, Chief Financial Officer, will present at the 29th Annual Canaccord Adams Global Growth Conference in Boston, MA on Thursday, August 13, 2009 at 8:30 a.m. (Eastern).

Hologic today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s premarket approval (PMA) application for the Adiana® permanent contraception system.

Hologic today announced that it has received Food and Drug Administration (FDA) clearance for its R2™ DigitalNow™ HD software application.

Hologic today announced that Glenn Muir, Chief Financial Officer, will present at the 8th Annual Needham Life Sciences Conference in New York on Wednesday, June 10, 2009 at 3:00 p.m. (Eastern) and the Jefferies 3rd Annual Healthcare Conference in New York on Wednesday, June 17, 2009 at 4:15 p.m. (Eastern).

Hologic today announced plans to release its second quarter fiscal 2009 operating results on Monday, May 4, 2009 after market close. In conjunction with the release, management will host a conference call on Monday, May 4, 2009 at 5:00 p.m. (eastern).

Hologic today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's premarket approval (PMA) applications for both the Cervista HPV HR (high risk) and the Cervista HPV 16/18 tests.

Hologic today announced that it has received a final order for 14 Selenia™ digital mammography systems with service contracts from Tromp Medical, the Hologic dealer in The Netherlands.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Raymond James 30th Annual Institutional Investors Conference being held March 9, 2009 at the JW Marriott Grande Lakes hotel in Orlando, FL.

Hologic today is announcing preliminary unaudited first quarter fiscal 2009 revenues and earnings per diluted share (EPS) in conjunction with a presentation by Hologic’s Chairman and Chief Executive Officer, Jack Cumming, at the J.P. Morgan 27th Annual Healthcare conference today, Monday, January 12, 2009, in San Francisco, CA, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time.

Hologic today announced that it has received CE marking approval for its Adiana® permanent contraception system. The Adiana system is designed to provide a minimally-invasive, non-incisional alternative to traditional, surgical means of female sterilization.